GILD Jun 2024 92.500 put
| Previous Close | 13.80 |
| Open | N/A |
| Bid | 14.90 |
| Ask | 17.05 |
| Strike | 92.50 |
| Expire Date | 2024-06-21 |
| Day's Range | 13.80 - 13.80 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11 |
PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) in conjunction with the World Hepatitis Summit ("Summit"). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit"
- PR Newswire
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis C, hepatitis B, and hepatitis D in conjunction with the World Hepatitis Summit ("Summit"). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon from 9
ZacksGilead Sciences (GILD) Stock Moves -0.84%: What You Should Know
In the most recent trading session, Gilead Sciences (GILD) closed at $68.07, indicating a -0.84% shift from the previous trading day.
